Maravai LifeSciences Holdings Inc. Class A (MRVI)
NASDAQ: MRVIHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MRVI stock chart
Technical analysisKey statistics
All statistics- Market cap
- $1.81B
- EPS (TTM)
- -$0.44
- Dividend yield
- None
- 52-week range
- 2.80 – 9.42
- Day range
- 6.91 – 7.17
- Volume / Avg
- 1.79M / 2.72M
- Beta
- —
- Shares outstanding
- 149.25M
52-week range
MRVI stock today
Shares of Maravai LifeSciences (MRVI) finished lower on Nov 20 at $6.98, a drop of 2.92% or $0.21 per share, versus the S&P 500's 3.70% decline. At this level, MRVI sits in the middle of its 52-week range of $2.80 to $9.42: 25.9% below the high, set on Aug 26, 2026 and 149.3% above the low. MRVI is up 114.8% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 86.1%.
Maravai LifeSciences has posted a net loss over the last twelve months (EPS of -$0.44), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Maravai LifeSciences
Company profileMaravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America. It operates through two segments: TRILINK and CYGNUS. The TRILINK segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, and oligonucleotide therapy, as well as molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA).
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Bernd Brust
- Headquarters
- San Diego, CA
- Employees
- 410
- IPO year
- 2020
- Website
- maravai.com
Financial highlights
Full financialsIn fiscal 2025, Maravai LifeSciences generated $185.7 million in revenue, down 28.3% from fiscal 2024, its first annual decline since 2024. Maravai LifeSciences reported a net loss of $130.8 million, compared with a loss of $144.8 million a year earlier. Gross margin was 18.3% (down from 41.8%) and operating margin -115.9%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $185.74M | $259.19M | $288.94M | $883.00M | $799.24M |
| Growth | -28.34% | -10.30% | -67.28% | +10.48% | +181.33% |
| Net income | $-130.77M | $-144.85M | $-119.03M | $220.21M | $182.04M |
| EPS (diluted) | $-0.90 | $-1.05 | $-0.90 | $1.67 | $1.56 |
Analyst forecast
ForecastConsensus (9 analysts)
buy
Avg. price target
$9.64+38.11%
- Strong buy 0
- Buy 6
- Hold 3
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 4, 2026
- EPS actual vs est.
- $-0.14 vs $-0.07
- Surprise
- -100.00%
MRVI news
All MRVI news- Maravai LifeSciences Holdings Consensus Price Target Raised 11.76% to $9.69NasdaqMRVI, HEI.A
- Maravai LifeSciences Holdings, Inc. Reports Third Quarter 2026 Financial ResultsNasdaq
- Maravai LifeSciences Holdings Non-GAAP EPS of -$0.03 beats by $0.03, revenue of $45.9M beats by $2.34MSeeking Alpha
- Maravai LifeSciences Reports Third Quarter 2026 Financial ResultsBusiness Wire
- Maravai LifeSciences Holdings Consensus Price Target Increased 11.84% to $8.67Nasdaq
- Maravai LifeSciences To Host Earnings Conference Call on Wednesday, November 4, 2026Business Wire
Maravai LifeSciences peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| ZYMEZymeworks Inc. | 26.14 | -2.68% | $1.81B | vs MRVI |
| SEPNSepterna Inc. | 38.61 | -1.51% | $1.84B | vs MRVI |
| VERAVera Therapeutics Inc. Class A | 25.45 | -4.86% | $1.84B | vs MRVI |
| IMNMImmunome Inc. | 15.69 | -5.54% | $1.85B | vs MRVI |
| BHVNBiohaven Ltd. | 12.39 | -9.23% | $1.87B | vs MRVI |
| ETONEton Pharmaceuticals Inc. | 60.85 | -0.83% | $1.76B | vs MRVI |
| STOKStoke Therapeutics Inc. | 26.81 | -0.45% | $1.75B | vs MRVI |
| TRAXFirst Tracks Biotherapeutics Inc. | 41.64 | -6.34% | $1.75B | vs MRVI |
Indexes, lists and sector
Maravai LifeSciences stock FAQ
What is Maravai LifeSciences's stock price today?
MRVI last traded at $6.98 as of Nov 20, 4:00 PM EST, down 2.92% on the day. Prices are delayed at least 15 minutes.
Who is Maravai LifeSciences's CEO?
Mr. Bernd Brust is the chief executive officer of Maravai LifeSciences Holdings Inc. Class A, which has about 410 employees.
What is the MRVI 52-week high?
The 52-week high for MRVI is $9.42 and the 52-week low is $2.80. The stock is currently 25.9% below its high.